AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Agena biosciences1/5/2024 These emerging variants may be associated with increased transmissibility, more severe disease, inability to be detected by specific viral diagnostic tests, decreased response to therapeutic agents, and evasion of natural or vaccine-induced immunity. This will allow for a more scalable and effective expansion of variant surveillance programs, while increasing the efficiency of sequencing-based new variant discovery."Įnhanced surveillance of SARS-CoV-2 variants is critical for the continued public health response to the COVID-19 pandemic. "A more effective approach is to divide testing between the MassARRAY System for monitoring existing, known variants and sequencing to discover new variants. Darryl Irwin, Vice President of Scientific Affairs. "Most surveillance methods rely on sequencing-based technologies, which have inherent limitations - cost, time-to-result, limit of detection, and high-complexity - that make them impractical for known variant screening," said Dr. This makes the new panel one of the highest throughput SARS-CoV-2 variant surveillance tests on the market, and at $25 per sample, a compelling alternative to more costly and complex sequencing technologies. For SARS-CoV-2, influenza A, and influenza B targets, the platform enables accurate detection with comprehensive coverage.Ĭlinical laboratories can process thousands of samples each day on a single MassARRAY instrument. The MassARRAY® technology is a benchtop system that provides timely and accurate analysis of up to 1000s of samples in a single day.
0 Comments
Read More
Leave a Reply. |